相关实验视频

Updated: Jul 17, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

在患有鼻癌的患者中,Cetuximab Plus同时进行放射治疗

Moriyasu Yamauchi¹, Yuki Sato², Tomoya Ishida²

¹Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine, Nabeshima, Japan yamamori@cc.saga-u.ac.jp.

In vivo (Athens, Greece)

|August 31, 2023

概括

对于鼻癌 (NPC),同时使用 cetuximab (BRT) 进行放射治疗是可以容忍的,但如果没有额外的化疗,对于晚期癌症是不够的. 为了找到最佳的治疗策略,需要进一步的研究.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学瘤学医学瘤学

背景情况:

鼻癌 (NPC) 治疗通常涉及并发化疗和放射治疗.
同时用 cetuximab (BRT) 进行放射治疗是NPC的潜在治疗选择.
没有诱导或助剂化疗的BRT对NPC的数据是有限的.

研究的目的:

评估在没有诱导化疗 (ICT) 或辅助化疗的情况下在NPC患者中BRT的疗效和安全性.
评估与这种治疗方法相关的治疗反应,生存率和不良事件.

主要方法:

2015年7月至2018年4月期间接受BRT治疗的七名NPC患者的回顾性评估.
分析治疗完成,反应率,复发,转移,存活率和不良事件.

主要成果:

所有七名患者都完成了BRT. 观察到的完全响应率为85.7%.
患有晚期 (≥T3) 疾病的患者经历了局部复发,一名T1-2患者发展了远程转移.
一年和三年总生存率分别为85.7%和47.6%. 常见的不良事件包括粘膜炎和皮肤炎.

结论:

对于NPC来说,BRT是可以容忍的,具有可管理的不良事件.
对于晚期 (≥T3) 疾病的NPC患者,单独的BRT似乎不足,这表明需要同时进行化疗.

关键词:

这就是BRT BRT BRT.这种药物是Cetuximab.鼻癌 (nasopharyngeal carcinoma) 是一种发生在鼻的癌症.辐射疗法辐射疗法

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...